t cells gamma delta

Engineered T Cells: CAR T Cell Therapy and Beyond

Purpose of review:¬†This article reviews the current data and future directions of engineered T cell therapies in non-Hodgkin lymphomas. Recent findings:¬†Currently, four chimeric antigen receptor (CAR) T cell products are approved: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel. These products differ in construct, indication, manufacturing, clinical trial design, and toxicity profile, but all are autologous products targeting CD19. Encouraging early data is also emerging with the use of these products in additional subtypes of B cell lymphoma. Alternative engineered T cell products are also in development, including dual CD19/22 targeting CAR T cells, CD30-directed CAR T cells, allogeneic CAR…
Read More
No widgets found. Go to Widget page and add the widget in Offcanvas Sidebar Widget Area.